BioSpectrum
the business of Bio & Health Sciences

# Lupin’s Alliance Partner Concord receives approval for Mycophenolic Acid Delayed Release Tablets

20 December 2019 | News

**It is a generic equivalent of Myfortic® Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation**

Lupin in alliance with Concord Biotech Limited (Concord) announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, to market the generic equivalent of Myfortic® Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, are indicated for:

- Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
- Use in combination with cyclosporine and corticosteroids.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic®) had an annual sales of approximately USD 174 million in the U.S. (IQVIA MAT September 2019).